Traws Pharma Inc TRAW
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 15.37M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 0.02
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 7
- Website
- https://www.trawspharma.com
Valuation
|
Metric
|
TRAW
|
|---|---|
Price/Earnings (Normalized) | 0.02 |
Price/Book Value | 3.86 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
TRAW
Financial Strength
|
Metric
|
TRAW
|
|---|---|
Quick Ratio | 0.87 |
Current Ratio | 0.93 |
Interest Coverage | — |
Quick Ratio
TRAW
Profitability
|
Metric
|
TRAW
|
|---|---|
Return on Assets (Normalized) | −168.23% |
Return on Equity (Normalized) | −1,146.18% |
Return on Invested Capital (Normalized) | −1,146.18% |
Return on Assets
TRAW
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@#&mTx | LOCK|B?Fvp | $129B | |||
| Moderna Inc
MRNA
| LOCK|mG@&ZCC | LOCK|!^ | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|C>nY@M | LOCK|>s^!p | $79B | |||
| argenx SE ADR
ARGX
| LOCK|?l#ZR> | LOCK|xqb | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|n!F^<%M | LOCK|w&^ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|MVFX<x | LOCK|?^t? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>MjMSFz | LOCK|>!l> | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|xrTVzw | LOCK|<^ | $24B | |||
| Incyte Corp
INCY
| LOCK|Fcb?&Bt | LOCK|Y? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|RY#!F<& | LOCK|RV | $14B |
United States